Ollie Watson received his PhD in Number Theory from University of Pennsylvania and has since worked in finance at D. E. Shaw and Tudor Capital, where he led a quantitative research team. He is an expert on optimization and statistical modeling in low signal-to-noise environments, and has taught courses on fitting predictive Bayesian models on noisy data.

Nicholas Firth studied for his PhD in Chemoinformatics at the Institute of Cancer Research, where he developed de novo design software. The software he developed uses a fragment-based approach to explore chemical space. Nick has a deep understanding of many computational chemistry algorithms, feature engineering and machine learning for molecules.

Anna graduated pre-med from Northwestern University as a neuroscience major. Post pre-med, she studied computer science. She previously helped businesses implement digital tools at a tech consulting company. She now applies her background knowledge in both computer science, business and science to run Evariste.

Zoë Walters is a lecturer in translational epigenomics in the school of Cancer Sciences and is a Module Lead on the MSc Genomics within the Faculty of Medicine at Southampton. Zoë is a highly experienced cancer biologist whose expertise lies in target identification and validation in cancer and developmental disorders. Zoë has 18+ years' experience in molecular genetics, developmental biology, and cancer biology.

Mike Waring holds the Chair of Medicinal Chemistry at Newcastle University, he is Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit and Director of the EPSRC Centre for Doctoral Training in Molecular Sciences. He was Principal Scientist in Medicinal Chemistry at AstraZeneca. He is a highly experienced medicinal chemist with a track record of delivering drug-discovery projects through the clinic.

Charles has a finance background with a focus on investing, fundraising, and building technology focused businesses. This experience was gained during his tenure at Silver Lake Partners and more recently at QuantPort, a multi-billion dollar quantitative fund. His expertise covers investment and business development, from deal-structuring through to recruiting raw talent.

Alfie received a PhD in Medicinal Chemistry from Newcastle University, where he worked on fragment based drug discovery. He then moved to the Institute of Cancer Research, working on lead optimization of PPI inhibitors. Alfie has worked on a variety of targets including kinases, bromodomains, sulfatases, PPIs, and E3 ligases.

Oliver studied for his Mathematics PhD at Oxford. He worked on developing new data analytic tools to describe the topology and geometry of data sets with interesting spatial structure, as well as the asymptotic topological properties of random simplicial complexes. Oliver develops statistically robust models applied to drug discovery.

Daniel received a PhD in Cell and Molecular Biology from the Francis Crick Institute, studying the signalling dynamics of the TGF-β family, before working with AstraZeneca to develop therapeutic antibodies. He then worked at the Institute of Cancer Research, where his work focused on understanding the mechanism of action of molecular glue-like small molecules.

Noah is a graduate of the University of Oxford where he received a MSc in Biochemistry. His research focused on molecular dynamic simulations of mitochondrial supercomplexes and their interactions with lipid molecules. Since joining Evariste Noah has been developing the structure-based virtual screening pipeline, enriching the ability of Evariste's Hit Discovery platform.

James graduated from his Mathematics doctorate from Magdalen College, University of Oxford, where he studied combinatorics, focusing on problems with an arithmetic flavor. James applies these techniques to solve combinatorial and statistical problems in drug discovery.

Florencia has a MSc in Genomics Informatics where she worked on identifying and validating novel therapeutic targets for Oesophageal Adenocarcinoma. She has conducted studies in oncology, infectious diseases, & clinical genetics. Florencia aims to identify novel druggable targets in areas of unmet clinical need.‍

Jan received a PhD in Medicinal Chemistry from the University of Southern Denmark, working on AMPK modulators. He then joined the Institute of Cancer Research, optimizing inhibitors of a kinesin motor protein and subsequently worked on the development of antibody-drug conjugates at AstraZeneca.